fluoxetine and Apoplexy studies

Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.

Research Excerpts

Excerpt	Relevance	Reference
"Post-stroke apathetic and depressive symptoms respond differently to fluoxetine treatment."	9.69	Does fluoxetine reduce apathetic and depressive symptoms after stroke? An analysis of the Efficacy oF Fluoxetine-a randomized Controlled Trial in Stroke trial data set. ( Lundström, E; Markus, HS; Mårtensson, B; Tay, J, 2023)
"We randomized 17 consecutive adults 1:1 to 90 days of fluoxetine 20 mg daily vs placebo within 10 days of an ischemic stroke causing isolated homonymous hemianopia."	9.69	FLUORESCE: A Pilot Randomized Clinical Trial of Fluoxetine for Vision Recovery After Acute Ischemic Stroke. ( Busza, A; Mahon, BZ; Prentiss, EK; Sahin, B; Schneider, CL; Williams, ZR, 2023)
"The EFFECTS (Efficacy of Fluoxetine—a Randomised Controlled Trial in Stroke) recently reported that 20 mg fluoxetine once daily for 6 months after acute stroke did not improve functional outcome but reduced depression and increased fractures and hyponatremia at 6 months."	9.41	Effects of Fluoxetine on Outcomes at 12 Months After Acute Stroke: Results From EFFECTS, a Randomized Controlled Trial. ( Borg, J; Dennis, MS; Greilert Norin, N; Hackett, ML; Hankey, GJ; Isaksson, E; Lundström, E; Mårtensson, B; Mead, GE; Näsman, P; Norrving, B; Sunnerhagen, KS; Wallén, H; Wester, P, 2021)
"We test the safety of fluoxetine post-ischemic stroke in sub-Saharan Africa."	9.41	Measuring Ambulation, Motor, and Behavioral Outcomes with Post-stroke Fluoxetine in Tanzania: The Phase II MAMBO Trial. ( Buma, DC; Chiwanga, F; Fasoli, SE; Gluckstein, J; Ismail, S; Kapina, B; Massawe, E; Mateen, FJ; Mukyanuzi, N; Mworia, NA; Okeng'o, K; Rice, DR; Vogel, AC; Wasserman, M, 2021)
" Fluoxetine enhances the National Institutes of Health Stroke Scale (NIHSS) score [mean difference (MD)=-0."	9.41	Recovery in Stroke Patients Treated With Fluoxetine Versus Placebo: A Pooled Analysis of 7,165 Patients. ( Ahmed, E; Doheim, MF; Elfil, M; Elsnhory, A; Fathy, A; Hagrass, AI; Hanbal, A; Hasan, MT; Ouerdane, Y; Ragab, KM, 2023)
"Fluoxetine improved FMMS and reduced anxiety and depression."	9.41	The efficacy and safety of fluoxetine versus placebo for stroke recovery: a meta-analysis of randomized controlled trials. ( Qin, G; Wu, J, 2023)
" This trial compared the functional outcomes of subjects poststroke receiving fluoxetine versus placebo."	9.41	Does the Initiation of Fluoxetine Postacute Stroke Result in Improved Functional Recovery?: A Critically Appraised Topic. ( Alcott, SB; Demaerschalk, BM; Knox, MG; Marks, LA; O'Carroll, CB; Wingerchuk, DM, 2021)
"The AFFINITY trial (Assessment of Fluoxetine in Stroke Recovery) reported that oral fluoxetine 20 mg daily for 6 months after acute stroke did not improve functional outcome and increased the risk of falls, bone fractures, and seizures."	9.41	Twelve-Month Outcomes of the AFFINITY Trial of Fluoxetine for Functional Recovery After Acute Stroke: AFFINITY Trial Steering Committee on Behalf of the AFFINITY Trial Collaboration. ( Almeida, OP; Anderson, CS; Billot, L; Dennis, MS; Etherton-Beer, C; Flicker, L; Ford, AH; Gommans, J; Hackett, ML; Hankey, GJ; Jan, S; Lundström, E; Lung, T; Mead, GE; Sunnerhagen, KS; Thang-Nguyen, H; Yi, Q, 2021)
"To investigate whether daily treatment with 20 mg of fluoxetine hydrochloride reduces the proportion of people affected by clinically significant symptoms of depression after stroke."	9.41	Depression Outcomes Among Patients Treated With Fluoxetine for Stroke Recovery: The AFFINITY Randomized Clinical Trial. ( Almeida, OP; Etherton-Beer, C; Flicker, L; Ford, A; Hackett, M; Hankey, GJ, 2021)
"To determine if fluoxetine 20 mg by mouth daily, given within 14 days of acute ischemic stroke, and taken for 90 days, is well-tolerated and safe with adequate adherence to justify a future randomized, controlled trial of fluoxetine in the United Republic of Tanzania."	9.34	MAMBO: Measuring ambulation, motor, and behavioral outcomes with post-stroke fluoxetine in Tanzania: Protocol of a phase II clinical trial. ( Buma, D; Chiwanga, F; Ismail, SS; Mateen, FJ; Okeng'o, K; Pothier, L; Vogel, AC, 2020)
"Studies have suggested that fluoxetine might improve neurological recovery after stroke, but the results remain inconclusive."	9.34	Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. ( Borg, J; Dennis, M; Hackett, ML; Hankey, GJ; Isaksson, E; Lundström, E; Mårtensson, B; Mead, G; Näsman, P; Norrving, B; Sunnerhagen, KS; Wallén, H; Wester, P, 2020)
"Our Cochrane review of selective serotonin inhibitors for stroke recovery indicated that fluoxetine may improve functional recovery, but the trials were small and most were at high risk of bias."	9.34	Fluoxetine to improve functional outcomes in patients after acute stroke: the FOCUS RCT. ( Dennis, M; Forbes, J; Graham, C; Hackett, M; Hankey, GJ; House, A; Lewis, S; Lundström, E; Mead, G; Sandercock, P, 2020)
"To investigate the effects of WAA combined with fluoxetine in the clinical treatment of post-stroke depression (PSD) ."	9.34	Wrist-ankle acupuncture and Fluoxetine in the treatment of post-stroke depression: a randomized controlled clinical trial. ( Qian, X; Shu, S; Yao, F; You, Y; Zhang, T; Zhou, S, 2020)
"Studies have suggested that fluoxetine could improve neurological recovery after stroke."	9.34	Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. ( , 2020)
"Trials of fluoxetine for recovery after stroke report conflicting results."	9.34	Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial. ( , 2020)
"The Fluoxetine Or Control Under Supervision (FOCUS)-Poland trial tested in a Polish cohort the hypothesis that fluoxetine improves recovery after stroke."	9.34	Fluoxetine for stroke recovery improvement - the doubleblind, randomised placebo-controlled FOCUS-Poland trial. ( Bembenek, JP; Członkowska, A; Głuszkiewicz, M; Kurczych, K; Kłysz, B; Mazur, A; Niewada, M, 2020)
"To evaluate the effect of fluoxetine on three-year recurrence rate of acute ischemic stroke."	9.27	Effect of fluoxetine on three-year recurrence in acute ischemic stroke: A randomized controlled clinical study. ( Cai, Z; Chang, X; Chen, S; Guo, Y; He, Y; Liang, Y; Tang, B; Zeng, S, 2018)
"The present study aimed to assess the effectiveness of oral citalopram, compared with fluoxetine and a placebo, in patients with post-stroke motor disabilities."	9.27	The efficacy comparison of citalopram, fluoxetine, and placebo on motor recovery after ischemic stroke: a double-blind placebo-controlled randomized controlled trial. ( Asadollahi, M; Karimialavijeh, E; Khanmoradi, Z; Ramezani, M, 2018)
"We investigated the effects of fluoxetine on the short-term and long-term neural functional prognoses after ischemic stroke."	9.22	Effects of Fluoxetine on Neural Functional Prognosis after Ischemic Stroke: A Randomized Controlled Study in China. ( Cai, ZL; Guo, Y; He, YT; Jiang, X; Tang, BS; Zeng, SL, 2016)
"To evaluate the effect of using fluoxetine at different time intervals after ischemic stroke on neurological functional prognosis in China."	9.22	Effect of using fluoxetine at different time windows on neurological functional prognosis after ischemic stroke. ( Cai, Z; Guo, Y; He, Y; Jiang, X; Ma, K; Tang, B; Zeng, S; Zhang, Y, 2016)
"Several small trials have suggested that fluoxetine improves neurological recovery from stroke."	9.20	The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: a study protocol for three multicentre randomised controlled trials. ( Dennis, M; Hackett, ML; Hankey, GJ; Lundström, E; Mead, G; Murray, V, 2015)
"In patients with ischaemic stroke and moderate to severe motor deficit, the early prescription of fluoxetine with physiotherapy enhanced motor recovery after 3 months."	9.15	Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. ( Albucher, JF; Arnaud, C; Bejot, Y; Berard, E; Chollet, F; Deltour, S; Guillon, B; Jaillard, A; Lamy, C; Loubinoux, I; Marque, P; Moulin, T; Niclot, P; Pariente, J; Tardy, J; Thalamas, C, 2011)
"Fluoxetine may improve the poststroke emotional disturbances."	9.13	Fluoxetine improves the quality of life in patients with poststroke emotional disturbances. ( Choi, J; Choi-Kwon, S; Kang, DW; Kim, JS; Kwon, SU, 2008)
"One hundred fifty (150) moderately to severely depressed patients as determined by a score >20 on the Hamilton Depression Scale (HDS) after a single ischemic or hemorrhagic stroke were randomly divided into the FEWP group (n = 60), the fluoxetine group (n = 60), and the placebo group (n = 30)."	9.13	The beneficial effects of the herbal medicine Free and Easy Wanderer Plus (FEWP) and fluoxetine on post-stroke depression. ( Chen, J; Ge, HY; Li, LT; Wang, SH; Yu, M; Yue, SW, 2008)
"The efficacy and safety of the selective serotonin reuptake inhibitor fluoxetine have rarely been studied in the treatment of poststroke emotional disturbances."	9.12	Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double-blind, placebo-controlled study. ( Choi, JM; Choi-Kwon, S; Han, SW; Kang, DW; Kim, JS; Kwon, SU, 2006)
" Moderate to severe depressed patients (determined by Hamilton Depression Scale (HDS) > 15, the Beck Depression Inventory (BDI) and the Clinical Global Impression (CGI) Scale) were randomized to receive either 20 mg/d fluoxetine or placebo for 3 months."	9.10	Early fluoxetine treatment of post-stroke depression--a three-month double-blind placebo-controlled study with an open-label long-term follow up. ( Baumhackl, U; Fruehwald, S; Gatterbauer, E; Rehak, P, 2003)
"This study compared nortriptyline and fluoxetine with placebo in the treatment of depression and in recovery from physical and cognitive impairments after stroke."	9.09	Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. ( Castillo, C; Curdue, K; Kopel, T; Kosier, JT; Newman, RM; Petracca, G; Robinson, RG; Schultz, SK; Starkstein, SE, 2000)
" Recent hemiplegic patients (<3 months) suffering from major depressive disorder (determined by International Classification of Diseases, 10th Revision, and Montgomery-Asberg Depression Rating Scale [MADRS] >19) were randomized to receive either 20 mg/d fluoxetine (FLX) or placebo for 6 weeks."	9.09	Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. ( Barat, M; Joseph, PA; Mazaux, JM; Petit, H; Wiart, L, 2000)
"To determine whether fluoxetine, at any dose, given within the first year after stroke to patients who did not have to have mood disorders at randomization reduced disability, dependency, neurological deficits and fatigue; improved motor function, mood, and cognition at the end of treatment and follow-up, with the same number or fewer adverse effects."	9.05	Fluoxetine for stroke recovery: Meta-analysis of randomized controlled trials. ( Barugh, A; Dennis, MS; Hackett, ML; Hankey, GJ; Hsieh, CF; Kutlubaev, M; Legg, L; Lundström, E; Mead, GE; Rudberg, AS; Soleimani, B; Tilney, R; Wu, S, 2020)
"Small trials have suggested that fluoxetine may improve neurological recovery from stroke."	8.95	The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical and health economic analysis plan for the trials and for the individual patient data meta-analysis. ( Dennis, M; Forbes, J; Gommans, J; Graham, C; Hackett, ML; Hankey, GJ; Isaksson, E; Lewis, S; Lundström, E; Mead, G; Näsman, P; Nguyen, HT; Rudberg, AS, 2017)
"Depression may affect patients' recovery and even their survival rate after stroke, but it is often overlooked or inadequately managed; data regarding the prophylactic efficacy and safety of fluoxetine are inconsistent in this setting."	8.86	Fluoxetine for the prophylaxis of poststroke depression in patients with stroke: a meta-analysis. ( Liu, F; Yi, ZM; Zhai, SD, 2010)
"Fluoxetine has shown superior efficacy compared with placebo in the treatment of depression in patients with HIV/AIDS, diabetes mellitus or stroke; however, it has not significantly improved depressive symptoms versus placebo in patients with cancer."	8.81	Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness. ( Cheer, SM; Goa, KL, 2001)
"Fluoxetine, a 5-HT uptake inhibitor, has been adopted for the treatment of post-stroke depression in recent years."	8.12	Fluoxetine regulates the neuronal differentiation of neural stem cells transplanted into rat brains after stroke by increasing the 5HT level. ( Chen, J; Hu, R; Li, C; Wei, N; Zheng, P; Zhu, Y, 2022)
" A randomized controlled trial of simple acupuncture combined with fluoxetine in the treatment of poststroke depression will be selected."	8.02	Simple acupuncture combined with fluoxetine in the treatment of poststroke depression: A protocol for systematic review and meta-analysis. ( Bi, J; Gao, L; Gong, P; Ma, X, 2021)
"Our study aimed to evaluate the effect of fluoxetine on morning blood pressure surge (MBPS) in patients with ischemic stroke."	8.02	The effect of fluoxetine on morning blood pressure surge in patients with ischemic stroke: a prospective preliminary clinical study. ( Cai, Z; Deng, J; Guo, Y; He, Y; Zhang, H; Zhang, Y, 2021)
"Three large trials of fluoxetine for stroke recovery (FOCUS (fluoxetine or control under supervision), AFFINITY (the Assessment oF FluoxetINe In sTroke recovery) and EFFECTS (Efficacy oF Fluoxetine-a randomisEd Controlled Trial in Stroke)) have been collaboratively designed with the same basic protocol to facilitate an individual patient data analysis (IPDM)."	7.96	Update to the FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical analysis plan for the trials and for the individual patient data meta-analysis. ( Billot, L; Dennis, M; Forbes, J; Graham, C; Hackett, ML; Hankey, GJ; Lewis, S; Lundström, E; Mead, GE; Näsman, P, 2020)
"To investigate whether fluoxetine improves poststroke dysphagia and to detect the potential relationship between serum brain-derived neurotrophic factor (BDNF) levels and fluoxetine effects."	7.88	Effects of Fluoxetine on Poststroke Dysphagia: A Clinical Retrospective Study. ( Huang, J; Liu, X; Luo, X; Tang, C; Wang, QM; Wang, Y; Wood, L; Xu, M, 2018)
"Fluoxetine, one of the selective serotonin reuptake inhibitor (SSRI) antidepressants, has been thought to be effective for treating post-stroke depression (PSD)."	7.85	Alleviative effects of fluoxetine on depressive-like behaviors by epigenetic regulation of BDNF gene transcription in mouse model of post-stroke depression. ( He, QW; Hu, B; Jin, HJ; Li, M; Li, YN; Mao, L; Pei, L; Wan, Y; Xia, YP; Yang, S; Yue, ZY; Zheng, H, 2017)
"We report on a patient who developed massive gastrointestinal hemorrhage related to the use of fluoxetine in combination with aspirin and clopidogrel."	7.85	Gastrointestinal Hemorrhage Related to Fluoxetine in a Patient With Stroke. ( Wee, TC, 2017)
"The serotonin selective reuptake inhibitor fluoxetine (Flx) has tried to treat patients suffered acute ischemic stroke because of its possible neuroprotective actions."	7.78	Optimal dosages of fluoxetine in the treatment of hypoxic brain injury induced by 3-nitropropionic acid: implications for the adjunctive treatment of patients after acute ischemic stroke. ( Sun, Y; Sun, ZQ; Yang, G; Zhou, CH; Zhu, BG; Zhu, RS, 2012)
"The fluoxetine for motor recovery after acute ischemic stroke study was a double blind, placebo-controlled trial examining the effects of fluoxetine in patients five- to 10 days after an ischemic stroke."	7.77	Listening to fluoxetine: a hot message from the FLAME trial of poststroke motor recovery. ( Cramer, SC, 2011)
"Spontaneous, nontraumatic intracerebral hemorrhage (ICH) is a subtype of stroke that causes a great amount of disability and economic and social burden."	6.78	Fluoxetine for motor recovery after acute intracerebral hemorrhage (FMRICH): study protocol for a randomized, double-blind, placebo-controlled, multicenter trial. ( Aguayo-Leytte, G; Arauz, A; Cruz-Estrada, Ede L; Huerta-Franco, MR; Marquez-Romero, JM; Ruiz-Franco, A; Ruiz-Sandoval, JL; Silos, H, 2013)
"Fluoxetine is an antidepressant which enhances serotonergic neurotransmission through selective inhibition of neuronal reuptake of serotonin."	6.55	Neuroplasticity and behavioral effects of fluoxetine after experimental stroke. ( Qu, H; Sun, X; Sun, Y; Xiao, T; Zhao, C; Zhao, S, 2017)
"Post-stroke apathetic and depressive symptoms respond differently to fluoxetine treatment."	5.69	Does fluoxetine reduce apathetic and depressive symptoms after stroke? An analysis of the Efficacy oF Fluoxetine-a randomized Controlled Trial in Stroke trial data set. ( Lundström, E; Markus, HS; Mårtensson, B; Tay, J, 2023)
"We randomized 17 consecutive adults 1:1 to 90 days of fluoxetine 20 mg daily vs placebo within 10 days of an ischemic stroke causing isolated homonymous hemianopia."	5.69	FLUORESCE: A Pilot Randomized Clinical Trial of Fluoxetine for Vision Recovery After Acute Ischemic Stroke. ( Busza, A; Mahon, BZ; Prentiss, EK; Sahin, B; Schneider, CL; Williams, ZR, 2023)
"Stroke is the leading neurologic cause of burden operationalized in terms of disability-adjusted life-years."	5.62	Fluoxetine for Stroke: A Mixed Bag of Outcomes. ( Andrade, C, 2021)
" Other study measures included age, sex, marital status, living arrangements, function before the stroke, depression before the stroke, modified Rankin Scale (mRS) score, and treatment with fluoxetine or placebo for 26 weeks."	5.51	Measures Associated With Early, Late, and Persistent Clinically Significant Symptoms of Depression 1 Year After Stroke in the AFFINITY Trial. ( Almeida, OP; Etherton-Beer, C; Flicker, L; Ford, AH; Hackett, ML; Hankey, GJ, 2022)
"Fluoxetine was orally administrated starting 1 week after ischemia, with a dose of 16mg/kg/day for 3 weeks."	5.42	Fluoxetine enhanced neurogenesis is not translated to functional outcome in stroke rats. ( Jolkkonen, J; Liu, T; Sun, X; Xiao, T; Zhao, C; Zhao, M; Zhao, S, 2015)
"The EFFECTS (Efficacy of Fluoxetine—a Randomised Controlled Trial in Stroke) recently reported that 20 mg fluoxetine once daily for 6 months after acute stroke did not improve functional outcome but reduced depression and increased fractures and hyponatremia at 6 months."	5.41	Effects of Fluoxetine on Outcomes at 12 Months After Acute Stroke: Results From EFFECTS, a Randomized Controlled Trial. ( Borg, J; Dennis, MS; Greilert Norin, N; Hackett, ML; Hankey, GJ; Isaksson, E; Lundström, E; Mårtensson, B; Mead, GE; Näsman, P; Norrving, B; Sunnerhagen, KS; Wallén, H; Wester, P, 2021)
"We test the safety of fluoxetine post-ischemic stroke in sub-Saharan Africa."	5.41	Measuring Ambulation, Motor, and Behavioral Outcomes with Post-stroke Fluoxetine in Tanzania: The Phase II MAMBO Trial. ( Buma, DC; Chiwanga, F; Fasoli, SE; Gluckstein, J; Ismail, S; Kapina, B; Massawe, E; Mateen, FJ; Mukyanuzi, N; Mworia, NA; Okeng'o, K; Rice, DR; Vogel, AC; Wasserman, M, 2021)
" Fluoxetine enhances the National Institutes of Health Stroke Scale (NIHSS) score [mean difference (MD)=-0."	5.41	Recovery in Stroke Patients Treated With Fluoxetine Versus Placebo: A Pooled Analysis of 7,165 Patients. ( Ahmed, E; Doheim, MF; Elfil, M; Elsnhory, A; Fathy, A; Hagrass, AI; Hanbal, A; Hasan, MT; Ouerdane, Y; Ragab, KM, 2023)
"Fluoxetine improved FMMS and reduced anxiety and depression."	5.41	The efficacy and safety of fluoxetine versus placebo for stroke recovery: a meta-analysis of randomized controlled trials. ( Qin, G; Wu, J, 2023)
" This trial compared the functional outcomes of subjects poststroke receiving fluoxetine versus placebo."	5.41	Does the Initiation of Fluoxetine Postacute Stroke Result in Improved Functional Recovery?: A Critically Appraised Topic. ( Alcott, SB; Demaerschalk, BM; Knox, MG; Marks, LA; O'Carroll, CB; Wingerchuk, DM, 2021)
"The AFFINITY trial (Assessment of Fluoxetine in Stroke Recovery) reported that oral fluoxetine 20 mg daily for 6 months after acute stroke did not improve functional outcome and increased the risk of falls, bone fractures, and seizures."	5.41	Twelve-Month Outcomes of the AFFINITY Trial of Fluoxetine for Functional Recovery After Acute Stroke: AFFINITY Trial Steering Committee on Behalf of the AFFINITY Trial Collaboration. ( Almeida, OP; Anderson, CS; Billot, L; Dennis, MS; Etherton-Beer, C; Flicker, L; Ford, AH; Gommans, J; Hackett, ML; Hankey, GJ; Jan, S; Lundström, E; Lung, T; Mead, GE; Sunnerhagen, KS; Thang-Nguyen, H; Yi, Q, 2021)
"To investigate whether daily treatment with 20 mg of fluoxetine hydrochloride reduces the proportion of people affected by clinically significant symptoms of depression after stroke."	5.41	Depression Outcomes Among Patients Treated With Fluoxetine for Stroke Recovery: The AFFINITY Randomized Clinical Trial. ( Almeida, OP; Etherton-Beer, C; Flicker, L; Ford, A; Hackett, M; Hankey, GJ, 2021)
"To determine if fluoxetine 20 mg by mouth daily, given within 14 days of acute ischemic stroke, and taken for 90 days, is well-tolerated and safe with adequate adherence to justify a future randomized, controlled trial of fluoxetine in the United Republic of Tanzania."	5.34	MAMBO: Measuring ambulation, motor, and behavioral outcomes with post-stroke fluoxetine in Tanzania: Protocol of a phase II clinical trial. ( Buma, D; Chiwanga, F; Ismail, SS; Mateen, FJ; Okeng'o, K; Pothier, L; Vogel, AC, 2020)
"Studies have suggested that fluoxetine might improve neurological recovery after stroke, but the results remain inconclusive."	5.34	Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. ( Borg, J; Dennis, M; Hackett, ML; Hankey, GJ; Isaksson, E; Lundström, E; Mårtensson, B; Mead, G; Näsman, P; Norrving, B; Sunnerhagen, KS; Wallén, H; Wester, P, 2020)
"Our Cochrane review of selective serotonin inhibitors for stroke recovery indicated that fluoxetine may improve functional recovery, but the trials were small and most were at high risk of bias."	5.34	Fluoxetine to improve functional outcomes in patients after acute stroke: the FOCUS RCT. ( Dennis, M; Forbes, J; Graham, C; Hackett, M; Hankey, GJ; House, A; Lewis, S; Lundström, E; Mead, G; Sandercock, P, 2020)
"To investigate the effects of WAA combined with fluoxetine in the clinical treatment of post-stroke depression (PSD) ."	5.34	Wrist-ankle acupuncture and Fluoxetine in the treatment of post-stroke depression: a randomized controlled clinical trial. ( Qian, X; Shu, S; Yao, F; You, Y; Zhang, T; Zhou, S, 2020)
"Studies have suggested that fluoxetine could improve neurological recovery after stroke."	5.34	Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. ( , 2020)
"Trials of fluoxetine for recovery after stroke report conflicting results."	5.34	Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial. ( , 2020)
"The Fluoxetine Or Control Under Supervision (FOCUS)-Poland trial tested in a Polish cohort the hypothesis that fluoxetine improves recovery after stroke."	5.34	Fluoxetine for stroke recovery improvement - the doubleblind, randomised placebo-controlled FOCUS-Poland trial. ( Bembenek, JP; Członkowska, A; Głuszkiewicz, M; Kurczych, K; Kłysz, B; Mazur, A; Niewada, M, 2020)
" EFFECTS is a Swedish, academic-led RCT of fluoxetine for stroke recovery."	5.27	Enhancing Recruitment Using Teleconference and Commitment Contract (ERUTECC): study protocol for a randomised, stepped-wedge cluster trial within the EFFECTS trial. ( Isaksson, E; Laska, AC; Lundström, E; Näsman, P; Wester, P, 2018)
"To evaluate the effect of fluoxetine on three-year recurrence rate of acute ischemic stroke."	5.27	Effect of fluoxetine on three-year recurrence in acute ischemic stroke: A randomized controlled clinical study. ( Cai, Z; Chang, X; Chen, S; Guo, Y; He, Y; Liang, Y; Tang, B; Zeng, S, 2018)
"The present study aimed to assess the effectiveness of oral citalopram, compared with fluoxetine and a placebo, in patients with post-stroke motor disabilities."	5.27	The efficacy comparison of citalopram, fluoxetine, and placebo on motor recovery after ischemic stroke: a double-blind placebo-controlled randomized controlled trial. ( Asadollahi, M; Karimialavijeh, E; Khanmoradi, Z; Ramezani, M, 2018)
"We investigated the effects of fluoxetine on the short-term and long-term neural functional prognoses after ischemic stroke."	5.22	Effects of Fluoxetine on Neural Functional Prognosis after Ischemic Stroke: A Randomized Controlled Study in China. ( Cai, ZL; Guo, Y; He, YT; Jiang, X; Tang, BS; Zeng, SL, 2016)
"To evaluate the effect of using fluoxetine at different time intervals after ischemic stroke on neurological functional prognosis in China."	5.22	Effect of using fluoxetine at different time windows on neurological functional prognosis after ischemic stroke. ( Cai, Z; Guo, Y; He, Y; Jiang, X; Ma, K; Tang, B; Zeng, S; Zhang, Y, 2016)
"Several small trials have suggested that fluoxetine improves neurological recovery from stroke."	5.20	The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: a study protocol for three multicentre randomised controlled trials. ( Dennis, M; Hackett, ML; Hankey, GJ; Lundström, E; Mead, G; Murray, V, 2015)
"To study the effect of early intervention of liver-soothing and Blood-activating decoction combined with acupuncture in improving neurological functions, depressive symptom and life quality of patients with post-stroke depression, and compare with fluoxetine hydrochloride."	5.17	[Effect of early intervention of liver-smoothing and blood-activating decoction combined with acupuncture on patients with post-stroke depression]. ( Bi, XL; Chen, CJ; Fan, ZJ; Hu, JF; Liu, TF; Liu, Y; Yang, PQ; Yu, ZH, 2013)
"In patients with ischaemic stroke and moderate to severe motor deficit, the early prescription of fluoxetine with physiotherapy enhanced motor recovery after 3 months."	5.15	Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. ( Albucher, JF; Arnaud, C; Bejot, Y; Berard, E; Chollet, F; Deltour, S; Guillon, B; Jaillard, A; Lamy, C; Loubinoux, I; Marque, P; Moulin, T; Niclot, P; Pariente, J; Tardy, J; Thalamas, C, 2011)
"During the 1-year follow-up period, and after adjusting for critical confounders including age, intensity of rehabilitation therapy, baseline stroke severity, and baseline Hamilton Depression Rating Scale, patients who received fluoxetine or nortriptyline had significantly greater improvement in modified Rankin Scale scores compared to patients who received placebo (t [156] = -3."	5.15	Effect of antidepressants on the course of disability following stroke. ( Adams, HP; Davis, PH; Jang, M; Jorge, RE; Leira, EC; Mikami, K; Robinson, RG, 2011)
"Fluoxetine may improve the poststroke emotional disturbances."	5.13	Fluoxetine improves the quality of life in patients with poststroke emotional disturbances. ( Choi, J; Choi-Kwon, S; Kang, DW; Kim, JS; Kwon, SU, 2008)
"One hundred fifty (150) moderately to severely depressed patients as determined by a score >20 on the Hamilton Depression Scale (HDS) after a single ischemic or hemorrhagic stroke were randomly divided into the FEWP group (n = 60), the fluoxetine group (n = 60), and the placebo group (n = 30)."	5.13	The beneficial effects of the herbal medicine Free and Easy Wanderer Plus (FEWP) and fluoxetine on post-stroke depression. ( Chen, J; Ge, HY; Li, LT; Wang, SH; Yu, M; Yue, SW, 2008)
"Based on available RCTs of fluoxetine and citalopram, SSRIs used for 6 months doubled the risk of fractures in stroke survivors."	5.12	Risk of Fractures in Stroke Patients Treated With a Selective Serotonin Reuptake Inhibitor: A Systematic Review and Meta-Analysis. ( Almeida, OP; Hankey, GJ; Jones, JS; Kimata, R, 2021)
"The efficacy and safety of the selective serotonin reuptake inhibitor fluoxetine have rarely been studied in the treatment of poststroke emotional disturbances."	5.12	Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double-blind, placebo-controlled study. ( Choi, JM; Choi-Kwon, S; Han, SW; Kang, DW; Kim, JS; Kwon, SU, 2006)
"WLC is effective in treating patients with poststroke depression and shows synergism with fluoxetine."	5.12	[Observation on effect of Wuling Capsule in treating poststroke depression]. ( Xu, B; Zhang, SJ; Zhou, WY, 2007)
"The authors randomly assigned nondepressed patients at least 3 months poststroke to receive nortriptyline, fluoxetine, or placebo for 3 months using double-blind methodology."	5.12	Risk factors for and correlates of poststroke depression following discontinuation of antidepressants. ( Fiedorowicz, JG; Robinson, RG; Takezawa, K, 2007)
" Moderate to severe depressed patients (determined by Hamilton Depression Scale (HDS) > 15, the Beck Depression Inventory (BDI) and the Clinical Global Impression (CGI) Scale) were randomized to receive either 20 mg/d fluoxetine or placebo for 3 months."	5.10	Early fluoxetine treatment of post-stroke depression--a three-month double-blind placebo-controlled study with an open-label long-term follow up. ( Baumhackl, U; Fruehwald, S; Gatterbauer, E; Rehak, P, 2003)
"A total of 104 patients were randomly assigned to receive a 12-week double-blind course of nortriptyline, fluoxetine, or placebo early in the recovery period after a stroke."	5.10	Mortality and poststroke depression: a placebo-controlled trial of antidepressants. ( Arndt, S; Jorge, RE; Robinson, RG; Starkstein, S, 2003)
"This study compared nortriptyline and fluoxetine with placebo in the treatment of depression and in recovery from physical and cognitive impairments after stroke."	5.09	Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. ( Castillo, C; Curdue, K; Kopel, T; Kosier, JT; Newman, RM; Petracca, G; Robinson, RG; Schultz, SK; Starkstein, SE, 2000)
" Recent hemiplegic patients (<3 months) suffering from major depressive disorder (determined by International Classification of Diseases, 10th Revision, and Montgomery-Asberg Depression Rating Scale [MADRS] >19) were randomized to receive either 20 mg/d fluoxetine (FLX) or placebo for 6 weeks."	5.09	Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. ( Barat, M; Joseph, PA; Mazaux, JM; Petit, H; Wiart, L, 2000)
"To determine whether fluoxetine, at any dose, given within the first year after stroke to patients who did not have to have mood disorders at randomization reduced disability, dependency, neurological deficits and fatigue; improved motor function, mood, and cognition at the end of treatment and follow-up, with the same number or fewer adverse effects."	5.05	Fluoxetine for stroke recovery: Meta-analysis of randomized controlled trials. ( Barugh, A; Dennis, MS; Hackett, ML; Hankey, GJ; Hsieh, CF; Kutlubaev, M; Legg, L; Lundström, E; Mead, GE; Rudberg, AS; Soleimani, B; Tilney, R; Wu, S, 2020)
"Small trials have suggested that fluoxetine may improve neurological recovery from stroke."	4.95	The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical and health economic analysis plan for the trials and for the individual patient data meta-analysis. ( Dennis, M; Forbes, J; Gommans, J; Graham, C; Hackett, ML; Hankey, GJ; Isaksson, E; Lewis, S; Lundström, E; Mead, G; Näsman, P; Nguyen, HT; Rudberg, AS, 2017)
"Among identified clinical studies, a well-designed randomized, double-blind, and placebo-controlled study (FLAME - fluoxetine for motor recovery after acute ischemic stroke) demonstrated improved recovery of motor function in stroke patients receiving fluoxetine."	4.91	Selective serotonin reuptake inhibitors to improve outcome in acute ischemic stroke: possible mechanisms and clinical evidence. ( Barlinn, K; Illigens, BM; Kepplinger, J; Penzlin, AI; Reichmann, H; Siepmann, T; Weidner, K, 2015)
"Depression may affect patients' recovery and even their survival rate after stroke, but it is often overlooked or inadequately managed; data regarding the prophylactic efficacy and safety of fluoxetine are inconsistent in this setting."	4.86	Fluoxetine for the prophylaxis of poststroke depression in patients with stroke: a meta-analysis. ( Liu, F; Yi, ZM; Zhai, SD, 2010)
"Pharmacotherapy of aphasia had been discussed for the last twenty years with first bromocriptine and amphetamine and then serotoninergic, GABAergic and cholinergic agents."	4.84	Pharmacotherapy of aphasia: myth or reality? ( de Boissezon, X; de Boysson, C; Démonet, JF; Peran, P, 2007)
"Fluoxetine has shown superior efficacy compared with placebo in the treatment of depression in patients with HIV/AIDS, diabetes mellitus or stroke; however, it has not significantly improved depressive symptoms versus placebo in patients with cancer."	4.81	Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness. ( Cheer, SM; Goa, KL, 2001)
"Fluoxetine, a 5-HT uptake inhibitor, has been adopted for the treatment of post-stroke depression in recent years."	4.12	Fluoxetine regulates the neuronal differentiation of neural stem cells transplanted into rat brains after stroke by increasing the 5HT level. ( Chen, J; Hu, R; Li, C; Wei, N; Zheng, P; Zhu, Y, 2022)
" A randomized controlled trial of simple acupuncture combined with fluoxetine in the treatment of poststroke depression will be selected."	4.02	Simple acupuncture combined with fluoxetine in the treatment of poststroke depression: A protocol for systematic review and meta-analysis. ( Bi, J; Gao, L; Gong, P; Ma, X, 2021)
"Our study aimed to evaluate the effect of fluoxetine on morning blood pressure surge (MBPS) in patients with ischemic stroke."	4.02	The effect of fluoxetine on morning blood pressure surge in patients with ischemic stroke: a prospective preliminary clinical study. ( Cai, Z; Deng, J; Guo, Y; He, Y; Zhang, H; Zhang, Y, 2021)
"Three large trials of fluoxetine for stroke recovery (FOCUS (fluoxetine or control under supervision), AFFINITY (the Assessment oF FluoxetINe In sTroke recovery) and EFFECTS (Efficacy oF Fluoxetine-a randomisEd Controlled Trial in Stroke)) have been collaboratively designed with the same basic protocol to facilitate an individual patient data analysis (IPDM)."	3.96	Update to the FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical analysis plan for the trials and for the individual patient data meta-analysis. ( Billot, L; Dennis, M; Forbes, J; Graham, C; Hackett, ML; Hankey, GJ; Lewis, S; Lundström, E; Mead, GE; Näsman, P, 2020)
"To investigate whether fluoxetine improves poststroke dysphagia and to detect the potential relationship between serum brain-derived neurotrophic factor (BDNF) levels and fluoxetine effects."	3.88	Effects of Fluoxetine on Poststroke Dysphagia: A Clinical Retrospective Study. ( Huang, J; Liu, X; Luo, X; Tang, C; Wang, QM; Wang, Y; Wood, L; Xu, M, 2018)
"Fluoxetine, one of the selective serotonin reuptake inhibitor (SSRI) antidepressants, has been thought to be effective for treating post-stroke depression (PSD)."	3.85	Alleviative effects of fluoxetine on depressive-like behaviors by epigenetic regulation of BDNF gene transcription in mouse model of post-stroke depression. ( He, QW; Hu, B; Jin, HJ; Li, M; Li, YN; Mao, L; Pei, L; Wan, Y; Xia, YP; Yang, S; Yue, ZY; Zheng, H, 2017)
"We report on a patient who developed massive gastrointestinal hemorrhage related to the use of fluoxetine in combination with aspirin and clopidogrel."	3.85	Gastrointestinal Hemorrhage Related to Fluoxetine in a Patient With Stroke. ( Wee, TC, 2017)
"Fluoxetine, a selective serotonin reuptake inhibitor, exerts neuroprotective effects in a variety of neurological diseases including stroke, but the underlying mechanism remains obscure."	3.83	Fluoxetine protects against IL-1β-induced neuronal apoptosis via downregulation of p53. ( Bian, Y; Ding, J; Hu, G; Lu, M; Shan, H; Shu, Z; Xiao, M; Zhang, L; Zhu, J, 2016)
" Finally, we used therapeutic interventions to explore mechanisms that may be involved in producing this increase in jump latency by administering the anti-depressant fluoxetine prior to the long jump assay, and also tested for potential changes in anxiety levels after stroke."	3.81	So you think you can jump? A novel long jump assessment to detect deficits in stroked mice. ( Hurn, PD; Kumar, S; Martin, L; Mittal, N; Ofomata, A; Palmateer, J; Pan, J; Pandya, A; Schallert, T, 2015)
"The serotonin selective reuptake inhibitor fluoxetine (Flx) has tried to treat patients suffered acute ischemic stroke because of its possible neuroprotective actions."	3.78	Optimal dosages of fluoxetine in the treatment of hypoxic brain injury induced by 3-nitropropionic acid: implications for the adjunctive treatment of patients after acute ischemic stroke. ( Sun, Y; Sun, ZQ; Yang, G; Zhou, CH; Zhu, BG; Zhu, RS, 2012)
"The fluoxetine for motor recovery after acute ischemic stroke study was a double blind, placebo-controlled trial examining the effects of fluoxetine in patients five- to 10 days after an ischemic stroke."	3.77	Listening to fluoxetine: a hot message from the FLAME trial of poststroke motor recovery. ( Cramer, SC, 2011)
"Treatment with fluoxetine for 26 weeks did not change the prevalence of these thoughts compared with placebo."	3.11	Wishing to die or self-harm after stroke: A planned secondary analysis of the AFFINITY Randomised Controlled Trial. ( Almeida, OP; Etherton-Beer, C; Flicker, L; Ford, A; Hackett, M; Hankey, GJ, 2022)
"Poststroke depression is a serious and common complication of stroke, especially the ischemic poststroke depression."	2.90	Efficacy and mechanism of acupuncture for ischemic poststroke depression: Study protocol for a multicenter single-blinded randomized sham-controlled trial. ( Bai, W; Ding, S; Gan, Y; Li, M; Li, P; Lu, H; Meng, L; Meng, Z; Ren, X; Wang, F; Wang, L; Wang, Z; Zhang, B; Zhang, C; Zhang, Z; Zhao, H, 2019)
"Spontaneous, nontraumatic intracerebral hemorrhage (ICH) is a subtype of stroke that causes a great amount of disability and economic and social burden."	2.78	Fluoxetine for motor recovery after acute intracerebral hemorrhage (FMRICH): study protocol for a randomized, double-blind, placebo-controlled, multicenter trial. ( Aguayo-Leytte, G; Arauz, A; Cruz-Estrada, Ede L; Huerta-Franco, MR; Marquez-Romero, JM; Ruiz-Franco, A; Ruiz-Sandoval, JL; Silos, H, 2013)
"Unawareness of impairment (anosognosia) is a phenomenon associated with right hemisphere lesions."	2.72	Response of emotional unawareness after stroke to antidepressant treatment. ( Bria, P; Caltagirone, C; Ripa, A; Robinson, RG; Spalletta, G, 2006)
" Further studies are required to investigate the effect of chronic administration of fluoxetine on motor function."	2.70	[Post-ischemia neurologic recovery]. ( Albucher, JF; Chollet, F; Guiraud-Chaumeil, B; Loubinoux, I; Pariente, J, 2002)
"Stroke is a major cause of adult disability."	2.61	Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. ( Barugh, A; Dennis, M; Hackett, ML; Hankey, GJ; Hsieh, CF; Kutlubaev, MA; Legg, LA; Lundström, E; Mead, GE; Rudberg, AS; Soleimani, B; Tilney, R; Wu, S, 2019)
"Fluoxetine is an antidepressant which enhances serotonergic neurotransmission through selective inhibition of neuronal reuptake of serotonin."	2.55	Neuroplasticity and behavioral effects of fluoxetine after experimental stroke. ( Qu, H; Sun, X; Sun, Y; Xiao, T; Zhao, C; Zhao, S, 2017)
"Stroke is the major cause of adult disability."	2.48	Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. ( Claxton, A; Hackett, ML; Hankey, GJ; Hsieh, CF; Kutlubaev, MA; Lee, R; Mead, GE, 2012)
"Stroke is the leading neurologic cause of burden operationalized in terms of disability-adjusted life-years."	1.62	Fluoxetine for Stroke: A Mixed Bag of Outcomes. ( Andrade, C, 2021)
"Treatment with fluoxetine attenuated the expression of Htr2B mRNA, stimulated post-stroke neurogenesis in the subventricular zone and was associated with an improved anhedonic behavior and an increased activity in the forced swim test in aged animals."	1.43	Up-regulation of serotonin receptor 2B mRNA and protein in the peri-infarcted area of aged rats and stroke patients. ( Bădescu, GM; Bogdan, C; Buga, AM; Ciobanu, O; Di Napoli, M; Popa-Wagner, A; Slevin, M; Weston, R, 2016)
"Fluoxetine was orally administrated starting 1 week after ischemia, with a dose of 16mg/kg/day for 3 weeks."	1.42	Fluoxetine enhanced neurogenesis is not translated to functional outcome in stroke rats. ( Jolkkonen, J; Liu, T; Sun, X; Xiao, T; Zhao, C; Zhao, M; Zhao, S, 2015)

Research

Studies (106)

Authors

Clinical Trials (13)

Trial Overview

Trial Outcomes

Mean Percent Change in Field Points Tested

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	25 (23.58)	29.6817
2010's	43 (40.57)	24.3611
2020's	38 (35.85)	2.80

Authors	Studies
Lundström, E	15
Isaksson, E	4
Greilert Norin, N	1
Näsman, P	5
Wester, P	3
Mårtensson, B	3
Norrving, B	2
Wallén, H	2
Borg, J	2
Hankey, GJ	18
Hackett, ML	14
Mead, GE	8
Dennis, MS	3
Sunnerhagen, KS	4
Legg, LA	2
Rudberg, AS	4
Hua, X	1
Wu, S	3
Tilney, R	3
Lindgren, L	1
Kutlubaev, MA	3
Hsieh, CF	4
Barugh, AJ	1
Dennis, M	10
Mateen, FJ	2
Massawe, E	1
Mworia, NA	1
Ismail, S	1
Rice, DR	1
Vogel, AC	2
Kapina, B	1
Mukyanuzi, N	1
Buma, DC	1
Gluckstein, J	1
Wasserman, M	1
Fasoli, SE	1
Chiwanga, F	2
Okeng'o, K	2
Wei, N	1
Li, C	1
Zhu, Y	1
Zheng, P	1
Hu, R	1
Chen, J	2
Almeida, OP	8
Ford, AH	3
Etherton-Beer, C	5
Flicker, L	6
Kalbouneh, HM	1
Toubasi, AA	1
Albustanji, FH	1
Obaid, YY	1
Al-Harasis, LM	1
Elsnhory, A	1
Hasan, MT	1
Hagrass, AI	1
Hanbal, A	1
Fathy, A	1
Ahmed, E	1
Ouerdane, Y	1
Ragab, KM	1
Elfil, M	1
Doheim, MF	1
Chye, A	1
Gommans, J	3
Jan, S	2
Beer, CE	1
Delcourt, C	1
Billot, L	3
Anderson, CS	2
Stibrant Sunnerhagen, K	1
Yi, Q	2
Bompoint, S	1
Nguyen, TH	1
Lung, T	2
Tay, J	1
Markus, HS	2
Ford, A	3
Hackett, M	3
Schneider, CL	1
Prentiss, EK	1
Busza, A	1
Williams, ZR	1
Mahon, BZ	1
Sahin, B	1
Wu, J	1
Qin, G	1
Forbes, J	4
Graham, C	4
House, A	3
Lewis, S	4
Sandercock, P	2
Mead, G	6
Legg, L	1
Kutlubaev, M	1
Soleimani, B	2
Barugh, A	2
Ismail, SS	1
Buma, D	1
Pothier, L	1
Platz, T	1
You, Y	1
Zhang, T	1
Shu, S	1
Qian, X	1
Zhou, S	1
Yao, F	1
Kwakkel, G	1
Meskers, CGM	1
Ward, NS	1
Zahrai, A	1
Vahid-Ansari, F	1
Daigle, M	1
Albert, PR	1
Bembenek, JP	1
Niewada, M	1
Kłysz, B	1
Mazur, A	1
Kurczych, K	1
Głuszkiewicz, M	1
Członkowska, A	1
Wang, X	1
Xiong, J	1
Yang, J	2
Yuan, T	1
Jiang, Y	1
Zhou, X	1
Liao, K	1
Xu, L	1
Gong, P	1
Ma, X	1
Gao, L	1
Bi, J	1
He, Y	3
Deng, J	1
Zhang, Y	2
Cai, Z	3
Zhang, H	1
Guo, Y	4
Viktorisson, A	1
Andersson, EM	1
Knox, MG	1
Demaerschalk, BM	1
Alcott, SB	1
Marks, LA	1
Wingerchuk, DM	1
O'Carroll, CB	1
Thang-Nguyen, H	1
Andrade, C	1
Jones, JS	1
Kimata, R	1
Sun, Y	3
Liang, Y	2
Jiao, Y	1
Lin, J	1
Qu, H	2
Xu, J	1
Zhao, C	3
Sun, X	3
Zhao, S	2
Xiao, T	2
Jin, HJ	1
Pei, L	1
Li, YN	1
Zheng, H	1
Yang, S	1
Wan, Y	1
Mao, L	1
Xia, YP	1
He, QW	1
Li, M	2
Yue, ZY	1
Hu, B	1
Nguyen, HT	1
Laska, AC	1
Zeng, S	2
Chen, S	1
Tang, B	2
Chang, X	1
Asadollahi, M	1
Ramezani, M	1
Khanmoradi, Z	1
Karimialavijeh, E	1
Huang, J	1
Liu, X	1
Luo, X	1
Tang, C	1
Xu, M	1
Wood, L	1
Wang, Y	1
Wang, QM	1
van der Worp, HB	1
Hu, MZ	1
Wang, AR	1
Zhao, ZY	1
Chen, XY	1
Li, YB	1
Liu, B	1
Lu, H	1
Zhang, B	1
Ren, X	1
Meng, L	1
Bai, W	1
Wang, L	2
Wang, Z	1
Ding, S	1
Gan, Y	1
Zhang, Z	1
Li, P	1
Meng, Z	1
Zhao, H	1
Wang, F	1
Zhang, C	1
Heneghan, C	1
Mahtani, KR	1
Marquez-Romero, JM	1
Arauz, A	1
Ruiz-Sandoval, JL	1
Cruz-Estrada, Ede L	1
Huerta-Franco, MR	1
Aguayo-Leytte, G	1
Ruiz-Franco, A	1
Silos, H	1
Hu, JF	1
Chen, CJ	1
Bi, XL	1
Yu, ZH	1
Yang, PQ	1
Fan, ZJ	1
Liu, Y	1
Liu, TF	1
Corbett, AM	1
Sieber, S	1
Wyatt, N	1
Lizzi, J	1
Flannery, T	1
Sibbit, B	1
Sanghvi, S	1
Liu, T	1
Zhao, M	1
Jolkkonen, J	1
Murray, V	1
Ng, KL	1
Gibson, EM	1
Hubbard, R	1
Caffo, B	1
O'Brien, RJ	1
Krakauer, JW	1
Zeiler, SR	1
Mittal, N	1
Pan, J	1
Palmateer, J	1
Martin, L	1
Pandya, A	1
Kumar, S	1
Ofomata, A	1
Hurn, PD	1
Schallert, T	1
Siepmann, T	1
Penzlin, AI	1
Kepplinger, J	1
Illigens, BM	1
Weidner, K	1
Reichmann, H	1
Barlinn, K	1
Brunkhorst, R	1
Friedlaender, F	1
Ferreirós, N	1
Schwalm, S	1
Koch, A	1
Grammatikos, G	1
Toennes, S	1
Foerch, C	1
Pfeilschifter, J	1
Pfeilschifter, W	1
He, YT	1
Tang, BS	1
Cai, ZL	1
Zeng, SL	1
Jiang, X	2
Bardet, R	1
Moreno, JP	1
Rodriguez, T	1
Trémeau, AL	1
Hernandez, É	1
Bolot, AL	1
Ma, K	1
Shan, H	1
Bian, Y	1
Shu, Z	1
Zhang, L	1
Zhu, J	1
Ding, J	1
Lu, M	1
Xiao, M	1
Hu, G	1
Buga, AM	1
Ciobanu, O	1
Bădescu, GM	1
Bogdan, C	1
Weston, R	1
Slevin, M	1
Di Napoli, M	1
Popa-Wagner, A	1
Wee, TC	1
Choi-Kwon, S	3
Choi, J	2
Kwon, SU	3
Kang, DW	3
Kim, JS	3
Li, LT	1
Wang, SH	1
Ge, HY	1
Yue, SW	1
Yu, M	1
Yi, ZM	1
Liu, F	1
Zhai, SD	1
Chollet, F	2
Tardy, J	1
Albucher, JF	2
Thalamas, C	1
Berard, E	1
Lamy, C	1
Bejot, Y	1
Deltour, S	1
Jaillard, A	1
Niclot, P	1
Guillon, B	1
Moulin, T	1
Marque, P	1
Pariente, J	2
Arnaud, C	1
Loubinoux, I	2
Robinson, RG	9
Adams, HP	2
Mikami, K	1
Jorge, RE	2
Davis, PH	1
Leira, EC	1
Jang, M	1
Nau, JY	1
Gaillard, R	1
Mir, O	1
Gonzenbach, RR	1
Taegtmeyer, AB	1
Luft, A	1
Russmann, S	1
Cramer, SC	1
Chai, SB	1
Naik, SR	1
Sim, K	1
Majeed, F	1
Kamal, AK	1
Zhu, BG	1
Sun, ZQ	1
Yang, G	1
Zhou, CH	1
Zhu, RS	1
Ofek, K	1
Schoknecht, K	1
Melamed-Book, N	1
Heinemann, U	1
Friedman, A	1
Soreq, H	1
Budhdeo, S	1
Deluca, G	1
Lee, R	1
Claxton, A	1
Guiraud-Chaumeil, B	1
Fruehwald, S	1
Gatterbauer, E	1
Rehak, P	1
Baumhackl, U	1
Spalletta, G	2
Guida, G	1
Caltagirone, C	2
Yen, HL	1
Chan, W	1
Arndt, S	2
Starkstein, S	1
Dean, CE	1
Han, SW	1
Choi, JM	1
Ripa, A	1
Bria, P	1
Chan, KL	1
Campayo, A	1
Moser, DJ	2
Manev, R	1
Manev, H	1
de Boissezon, X	1
Peran, P	1
de Boysson, C	1
Démonet, JF	1
Narushima, K	2
Paradiso, S	1
Jorge, R	1
Ruddell, M	1
Spencer, A	1
Hill, K	1
Xu, B	1
Zhou, WY	1
Zhang, SJ	1
Fiedorowicz, JG	1
Takezawa, K	1
Schultz, SK	1
Castillo, C	1
Kopel, T	1
Kosier, JT	2
Newman, RM	1
Curdue, K	1
Petracca, G	1
Starkstein, SE	1
Wiart, L	1
Petit, H	1
Joseph, PA	1
Mazaux, JM	1
Barat, M	1
Cheer, SM	1
Goa, KL	1
Franco, K	1
Malhotra, S	1
Paolucci, S	1
Antonucci, G	1
Grasso, MG	1
Morelli, D	1
Troisi, E	1
Coiro, P	1
De Angelis, D	1
Rizzi, F	1
Bragoni, M	1
Detre, JA	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Establishing the Effect(s) and Safety of Fluoxetine Initiated in the Acute Phase of Stroke[NCT02683213]	Phase 3	1,500 participants (Actual)	Interventional	2014-10-20	Completed
Fluoxetine for Visual Recovery After Ischemic Stroke[NCT02737930]	Phase 2	17 participants (Actual)	Interventional	2016-05-31	Terminated (stopped due to Slow recruitment and lack of funding to expand to other sites.)
MAMBO: Measuring Ambulation, Motor, and Behavioral Outcomes With Post-Stroke Fluoxetine in Tanzania[NCT03728153]	Phase 2	34 participants (Actual)	Interventional	2019-11-26	Completed
Rehabkompassen® - a Novel Digital Tool for Facilitating Patient-tailored Rehabilitation in the Post-acute Continuum of Care After Stroke - A Multicenter Pragmatic Randomized Controlled Trial[NCT04915027]		1,106 participants (Anticipated)	Interventional	2020-08-26	Recruiting
Fluoxetine for Motor Recovery After Acute Intracerebral Hemorrhage (FMRICH): a Randomised Placebo-controlled Trial[NCT01737541]	Phase 3	32 participants (Actual)	Interventional	2012-11-30	Terminated (stopped due to Study recruitment was suspended due to lack of funding)
The Efficacy of Citalopram Treatment in Acute Stroke[NCT01937182]	Phase 2	642 participants (Actual)	Interventional	2013-09-30	Completed
E-Rehabilitation: Aerobic Resistance Training for Stroke Survivors[NCT02938000]		3 participants (Actual)	Interventional	2016-08-31	Completed
Pilot Study of Memantine for Enhanced Stroke Recovery[NCT02144584]	Early Phase 1	20 participants (Anticipated)	Interventional	2014-01-31	Active, not recruiting
FLOW Trial: Fluoxetine to Open the Critical Period Time Window to Improve Motor Recovery After Stroke[NCT03448159]	Phase 2	52 participants (Actual)	Interventional	2019-01-01	Completed
A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Agomelatine in the Prevention of Poststroke Depression[NCT05426304]	Phase 4	420 participants (Anticipated)	Interventional	2022-10-01	Not yet recruiting
Effects of 3 Months Daily Treatment With Selective Serotonin Reuptake Inhibitor (SSRI, Fluoxetine) on Motor Rehabilitation After Ischemic Stroke. FLAME Trial[NCT00657163]	Phase 2	100 participants (Anticipated)	Interventional	2005-03-31	Completed
Escitalopram and Language Intervention for Subacute Aphasia (ELISA)[NCT03843463]	Phase 2	88 participants (Anticipated)	Interventional	2021-07-18	Recruiting
Effect of Serotonin and Levodopa Functional Recovery in Patients With Cerebral Infarction[NCT02386475]	Phase 4	39 participants (Actual)	Interventional	2015-01-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Visual field recovery is defined as an improvement of more than 6 decibels (dB) in the threshold required to elicit a response at each point in the Humphrey visual field. This is based on the unidirectional test-retest variability of less than 3 dB reported in the Humphrey Field Analyzer manual. The endpoint will be an improvement in threshold values at test locations spanning more than 10 degrees horizontally or 15 degrees vertically in the Humphrey visual field in both eyes at 6 months, based on the definition of visual improvement used by Zhang et al. in their natural history study of stroke patients with hemianopia. (NCT02737930)
Timeframe: 6 months

Mean Percent Change in Post-stroke Retinal Nerve Fiber Layer Thickness

Intervention	percent of visual field points tested (Mean)
Fluoxetine	72.4
Placebo	32.1

This will be measured by spectral domain optical coherence tomography. Optical coherence tomography is a method of using low-coherence interferometry to determine the echo time delay and magnitude of backscattered light reflected off an object of interest. This method can be used to scan through the layers of a structured tissue sample such as the retina with very high axial resolution (3 to 15 μm), providing images demonstrating 3D structure. (NCT02737930)
Timeframe: baseline to 6 months

Median Change in Patient Health Questionnaire-9 Score

Intervention	percent change in microns (Mean)
Fluoxetine	-0.02
Placebo	-1.49

This is a self-report inventory used as a screening and diagnostic tool for depression (Appendix F). The 9 items are based on the 9 diagnostic criteria for depression included in the Diagnostic and Statistical Manual of Mental Disorders IV. The scales ranges from 0-27 with higher scores indicating worse outcome. (NCT02737930)
Timeframe: baseline to 6 months

Median Modified Rankin Scale Score

Intervention	score on a scale (Median)
Fluoxetine	-1
Placebo	0

This is a functional outcome measure widely used in stroke clinical trials, with a score of 0 indicating no disability, 6 indicating death, and scores of 2 or less generally accepted to indicate a favorable functional outcome. (NCT02737930)
Timeframe: 90 days

Number of Participants With >95% Recovery

Intervention	score on a scale (Median)
Fluoxetine	1
Placebo	2

Recovery is an improvement in the blind visual field. Participants were counted if the percentage of visual field that was blind was reduced by 95%. (NCT02737930)
Timeframe: 6 months

Percent Change in Mean Visual Function Questionnaire-25 Score

Intervention	participants (Number)
Fluoxetine	3
Placebo	1

The VFQ-25 consists of a base set of 25 vision targeted questions representing 11 vision-related constructs: global vision rating, difficulty with near vision activities, difficulty with distance vision activities, limitations in social functioning due to vision, role limitations due to vision, dependency on others due to vision, mental health symptoms due to vision, driving difficulties, limitations with peripheral and color vision, and ocular pain. The scores range from 0-100 with higher scores indicating better functioning. (NCT02737930)
Timeframe: baseline to 6 months

Percent Change in the Bionocularly Averaged Perimetric Mean Deviation

Intervention	percent change of units on a scale (Mean)
Fluoxetine	-11.2
Placebo	-14.9

24-2 Humphrey perimetry was completed for each eye (Zeiss HFAIIi, Swedish Interactive Threshold Algorithm (SITA) Standard, size III white target, fixation enforced, corrected for near vision). The cutoff of a sensitivity of 10 dB to define sighted versus blind test locations was chosen. Perimetric mean deviation is a summary statistic calculated by measuring the deviation from the expected threshold value for stimulation at each point in the visual field and taking an average, with possible values ranging from +2 to -32 dB. (NCT02737930)
Timeframe: baseline to 6 months

Fugl-Meyer Motor Scale Score for Assessment of Motor Function After Stroke

Intervention	percent change in dB (Mean)
Fluoxetine	64.4
Placebo	26.0

The Fugl Meyer motor scale is used to assess post-stroke motor recovery in stroke patients. It is scored on a scale from 0 to 100, with lower scores indicating greater disability. It evaluates both lower and upper extremities for motor performance: 66 points are allocated to the upper extremities, 34 to the lower extremities. The two extremities are summed to achieve the total score. (NCT03728153)
Timeframe: 90 days following acute, ischemic stroke

Modified Rankin Scale

Intervention	score on a scale (Mean)
20mg Dose	62.7

Validated instrument for measuring the degree of disability in stroke patients. The modified Rankin Scale is based on a physicians subjective evaluation. The scale ranges from 0, indicating perfect health, to 6, indicating that the patient is dead. (NCT03728153)
Timeframe: 90 days following acute, ischemic stroke

Montgomery-Asberg Depression Rating Scale

Intervention	score on a scale (Median)
20mg Dose	2

10-item questionnaire used to evaluate the severity of a patient's depressive symptoms. Each item is scored on a scale from 0 to 6, the scores are summed, and the total score (0 to 60 points) is reported. The greater the score, the more severe the degree of depression. (NCT03728153)
Timeframe: 90 days following acute, ischemic stroke

Serum Alanine Aminotransferase (ALT)

Intervention	units on a scale (Mean)
20mg Dose	5.6

Hepatic impairment was measured by elevation of hepatic enzyme (serum alanine aminotransferase; ALT) of >120 U/L (NCT03728153)
Timeframe: 90 days

Serum Sodium Concentration

Intervention	U/L (Mean)
20mg Dose	28

Serum Sodium Concentration was measured in mmol/L. Hyponatremia was considered as <125 mmol/L. (NCT03728153)
Timeframe: 90 days following acute, ischemic stroke

The Patient Health Questionnaire-9 (PHQ-9) Scale for Measuring Depression

Intervention	mmol/L (Mean)
20mg Dose	138.7

The PHQ-9 is a validated 9-point questionnaire for measuring depression symptom severity. Each question is scored from 0-3. Answers are summed and the total score (0 to 27) is reported. The greater the score, the greater the severity of depression. (NCT03728153)
Timeframe: 90 days following acute ischemic stroke

Article	Year
Fluoxetine regulates the neuronal differentiation of neural stem cells transplanted into rat brains after stroke by increasing the 5HT level. Neuroscience letters, 2022, 02-16, Volume: 772 Topics: Animals; Brain; Fluoxetine; Male; Mitogen-Activated Protein Kinase 1; Neural Stem Cells; Neurogenesi	2022
The global burden of stroke, and fluoxetine for stroke recovery. International journal of stroke : official journal of the International Stroke Society, 2020, Volume: 15, Issue:4 Topics: Fluoxetine; Humans; Recovery of Function; Selective Serotonin Reuptake Inhibitors; Stroke	2020
Do Selective Serotonin Reuptake Inhibitors (SSRIs) Promote Stroke Recovery within the First Year After Stroke? - A Cochrane Review Summary with Commentary. PM & R : the journal of injury, function, and rehabilitation, 2020, Volume: 12, Issue:6 Topics: Fluoxetine; Humans; Selective Serotonin Reuptake Inhibitors; Stroke	2020
Time for the next stage of stroke recovery trials. The Lancet. Neurology, 2020, Volume: 19, Issue:8 Topics: Clinical Trials as Topic; Fluoxetine; Humans; Recovery of Function; Selective Serotonin Reuptake Inh	2020
Fluoxetine-induced recovery of serotonin and norepinephrine projections in a mouse model of post-stroke depression. Translational psychiatry, 2020, 09-30, Volume: 10, Issue:1 Topics: Animals; Depression; Fluoxetine; Mice; Norepinephrine; Serotonin; Stroke	2020
Update to the FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical analysis plan for the trials and for the individual patient data meta-analysis. Trials, 2020, Nov-25, Volume: 21, Issue:1 Topics: Aged; Brain Ischemia; Data Interpretation, Statistical; Female; Fluoxetine; Humans; Male; Meta-Analy	2020
Simple acupuncture combined with fluoxetine in the treatment of poststroke depression: A protocol for systematic review and meta-analysis. Medicine, 2021, Mar-12, Volume: 100, Issue:10 Topics: Activities of Daily Living; Acupuncture Therapy; Combined Modality Therapy; Depression; Fluoxetine;	2021
The effect of fluoxetine on morning blood pressure surge in patients with ischemic stroke: a prospective preliminary clinical study. Blood pressure monitoring, 2021, Aug-01, Volume: 26, Issue:4 Topics: Blood Pressure; Blood Pressure Monitoring, Ambulatory; Brain Ischemia; Circadian Rhythm; Fluoxetine;	2021
Fluoxetine for Stroke: A Mixed Bag of Outcomes. The Journal of clinical psychiatry, 2021, 06-08, Volume: 82, Issue:3 Topics: Depression; Fluoxetine; Humans; Outcome Assessment, Health Care; Selective Serotonin Reuptake Inhibi	2021
Comparative efficacy and acceptability of antidepressant treatment in poststroke depression: a multiple-treatments meta-analysis. BMJ open, 2017, Aug-03, Volume: 7, Issue:8 Topics: Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depression; Depre	2017
Alleviative effects of fluoxetine on depressive-like behaviors by epigenetic regulation of BDNF gene transcription in mouse model of post-stroke depression. Scientific reports, 2017, 11-02, Volume: 7, Issue:1 Topics: Animals; Antidepressive Agents, Second-Generation; Brain-Derived Neurotrophic Factor; Depression; De	2017
Effects of Fluoxetine on Poststroke Dysphagia: A Clinical Retrospective Study. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2018, Volume: 27, Issue:11 Topics: Aged; Aged, 80 and over; Biomarkers; Brain-Derived Neurotrophic Factor; Chi-Square Distribution; Deg	2018
Fluoxetine and recovery after stroke. Lancet (London, England), 2019, 01-19, Volume: 393, Issue:10168 Topics: Double-Blind Method; Fluoxetine; Humans; Selective Serotonin Reuptake Inhibitors; Stroke	2019
Antidepressant-like effects of paeoniflorin on post-stroke depression in a rat model. Neurological research, 2019, Volume: 41, Issue:5 Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; CA1 Region, Hippocampal; Cyclic A	2019
Increasing neurogenesis with fluoxetine, simvastatin and ascorbic Acid leads to functional recovery in ischemic stroke. Recent patents on drug delivery & formulation, 2015, Volume: 9, Issue:2 Topics: Animals; Ascorbic Acid; Brain; Brain Ischemia; Drug Therapy, Combination; Female; Fluoxetine; Male;	2015
Fluoxetine enhanced neurogenesis is not translated to functional outcome in stroke rats. Neuroscience letters, 2015, Aug-31, Volume: 603 Topics: Animals; Brain Infarction; Corpus Striatum; Dendrites; Dentate Gyrus; Fluoxetine; Ischemic Attack, T	2015
Fluoxetine Maintains a State of Heightened Responsiveness to Motor Training Early After Stroke in a Mouse Model. Stroke, 2015, Volume: 46, Issue:10 Topics: Animals; Behavior, Animal; Disease Models, Animal; Fluoxetine; Male; Mice; Motor Activity; Motor Cor	2015
So you think you can jump? A novel long jump assessment to detect deficits in stroked mice. Journal of neuroscience methods, 2015, Dec-30, Volume: 256 Topics: Animals; Anxiety; Disease Models, Animal; Female; Fluoxetine; Hindlimb; Infarction, Middle Cerebral	2015
Alterations of the Ceramide Metabolism in the Peri-Infarct Cortex Are Independent of the Sphingomyelinase Pathway and Not Influenced by the Acid Sphingomyelinase Inhibitor Fluoxetine. Neural plasticity, 2015, Volume: 2015 Topics: Animals; Ceramides; Cerebral Cortex; Cerebral Infarction; Enzyme Inhibitors; Fluoxetine; Intracrania	2015
[A resistant diarrhea]. Presse medicale (Paris, France : 1983), 2016, Volume: 45, Issue:3 Topics: Aged, 80 and over; Anti-Ulcer Agents; Antidepressive Agents; Antidiarrheals; Colitis; Comorbidity; D	2016
Fluoxetine protects against IL-1β-induced neuronal apoptosis via downregulation of p53. Neuropharmacology, 2016, Volume: 107 Topics: Animals; Anisomycin; Apoptosis; bcl-2-Associated X Protein; Brain Ischemia; Cell Line, Tumor; Diseas	2016
Up-regulation of serotonin receptor 2B mRNA and protein in the peri-infarcted area of aged rats and stroke patients. Oncotarget, 2016, Apr-05, Volume: 7, Issue:14 Topics: Age Factors; Aged; Aged, 80 and over; Animals; Brain; Depression; Disease Models, Animal; Female; Fl	2016
Gastrointestinal Hemorrhage Related to Fluoxetine in a Patient With Stroke. American journal of physical medicine & rehabilitation, 2017, Volume: 96, Issue:11 Topics: Fluoxetine; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Selective Serotonin Reuptake Inh	2017
Selective serotonin-reuptake inhibitors and recovery after stroke. The Lancet. Neurology, 2011, Volume: 10, Issue:2 Topics: Depression; Fluoxetine; Humans; Recovery of Function; Selective Serotonin Reuptake Inhibitors; Strok	2011
[CVA: new indication for Prozac?]. Revue medicale suisse, 2011, Feb-09, Volume: 7, Issue:281 Topics: Fluoxetine; Humans; Motor Skills; Neuroprotective Agents; Recovery of Function; Stroke; Treatment Ou	2011
Fluoxetine and motor recovery after ischaemic stroke. The Lancet. Neurology, 2011, Volume: 10, Issue:6 Topics: Animals; Aryl Hydrocarbon Hydroxylases; Brain Ischemia; Clopidogrel; Cytochrome P-450 CYP2C19; Drug	2011
Fluoxetine and motor recovery after ischaemic stroke. The Lancet. Neurology, 2011, Volume: 10, Issue:6 Topics: Animals; Aryl Hydrocarbon Hydroxylases; Brain Ischemia; Clopidogrel; Cytochrome P-450 CYP2C19; Drug	2011
Listening to fluoxetine: a hot message from the FLAME trial of poststroke motor recovery. International journal of stroke : official journal of the International Stroke Society, 2011, Volume: 6, Issue:4 Topics: Double-Blind Method; Fluoxetine; Humans; Motor Activity; Randomized Controlled Trials as Topic; Reco	2011
MELAS associated pathological hyperemotionalism: a case report. Annals of the Academy of Medicine, Singapore, 2011, Volume: 40, Issue:9 Topics: Affective Symptoms; Female; Fluoxetine; Humans; MELAS Syndrome; Middle Aged; Selective Serotonin Reu	2011
Optimal dosages of fluoxetine in the treatment of hypoxic brain injury induced by 3-nitropropionic acid: implications for the adjunctive treatment of patients after acute ischemic stroke. CNS neuroscience & therapeutics, 2012, Volume: 18, Issue:7 Topics: Animals; Brain Ischemia; Fluoxetine; Hypoxia, Brain; Male; Mice; Nitro Compounds; Propionates; Rando	2012
Fluoxetine induces vasodilatation of cerebral arterioles by co-modulating NO/muscarinic signalling. Journal of cellular and molecular medicine, 2012, Volume: 16, Issue:11 Topics: Acetylcholinesterase; Animals; Arterioles; Atropine; Calcium; Cells, Cultured; Cerebral Cortex; Dise	2012
BDNF: a possible explanation of findings from the FLAME trial. International journal of stroke : official journal of the International Stroke Society, 2012, Volume: 7, Issue:6 Topics: Fluoxetine; Humans; Motor Activity; Recovery of Function; Selective Serotonin Reuptake Inhibitors; S	2012
Is left stroke a risk-factor for selective serotonin reuptake inhibitor antidepressant treatment resistance? Journal of neurology, 2003, Volume: 250, Issue:4 Topics: Administration, Oral; Aged; Cognition; Depressive Disorder; Drug Resistance; Female; Fluoxetine; Fun	2003
An East-West approach to the management of central post-stroke pain. Cerebrovascular diseases (Basel, Switzerland), 2003, Volume: 16, Issue:1 Topics: Acetates; Acupuncture; Aged; Amines; Amitriptyline; Analgesics, Opioid; Antidepressive Agents, Secon	2003
Mortality and poststroke depression. The American journal of psychiatry, 2004, Volume: 161, Issue:8 Topics: Antidepressive Agents; Brain-Derived Neurotrophic Factor; Comorbidity; Depressive Disorder; Fluoxeti	2004
Could treatment with arundic acid (ONO-2506) increase vulnerability for depression? Medical hypotheses, 2006, Volume: 67, Issue:5 Topics: Alzheimer Disease; Animals; Caprylates; Clinical Trials as Topic; Comorbidity; Depression; Disease M	2006
Poststroke depression. The American journal of psychiatry, 2001, Volume: 158, Issue:4 Topics: Aged; Antidepressive Agents, Tricyclic; Depressive Disorder; Fluoxetine; Humans; Middle Aged; Nortri	2001
Post-stroke depression, antidepressant treatment and rehabilitation results. A case-control study. Cerebrovascular diseases (Basel, Switzerland), 2001, Volume: 12, Issue:3 Topics: Activities of Daily Living; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; C	2001
Imaging stroke recovery: lessons from Prozac. Annals of neurology, 2001, Volume: 50, Issue:6 Topics: Fluoxetine; Humans; Magnetic Resonance Imaging; Motor Cortex; Motor Skills; Recovery of Function; Se	2001

fluoxetine and Apoplexy